Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival

被引:65
作者
Webster, W. Scott
Lohse, Christine M.
Thompson, R. Houston
Dong, Haidong
Frigola, Xavier
Dicks, Demetrius L.
Sengupta, Shomik
Frank, Igor
Leibovich, Bradley C.
Blute, Michael L.
Cheville, John C.
Kwon, Eugene D.
机构
[1] Mayo Clin, Dept Urol, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA
[3] Mayo Clin, Dept Immunol, Rochester, MN 55905 USA
[4] Mayo Clin, Dept Pathol, Rochester, MN 55905 USA
关键词
kidney cancer; nephrectomy; prognosis; lymphocyte; treatment;
D O I
10.1002/cncr.21951
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. The impact of mononuclear cell infiltration on renal cell carcinoma (RCC) biology has been controversial, previously reported to be associated with either a favorable or unfavorable prognosis. The objective of the current study was to evaluate associations between mononuclear cell infiltration in routinely prepared paraffin-embedded specimens with survival in patients with clear-cell RCC. METHODS. A total of 306 patients were identified treated with nephrectomy for clear-cell RCC between 1990 and 1994. A single urologic pathologist, blinded to patient outcome, reviewed the specimens and quantified the extent of mononuclear cell infiltration as absent, focal, moderate, or marked. Cancer-specific survival was estimated using the Kaplan-Meier method. Associations of mononuclear cell infiltration with death from RCC were assessed using Cox proportional hazards regression models. RESULTS. At last follow-up, 173 of the 306 patients studied had died, including 96 patients who died from RCC. Mononuclear cell infiltration was absent in 165 (54%), focal in 70 (23%), moderate in 53 (17%), and marked in 18 (6%). Univariately, patients with specimens that had mononuclear cell infiltration were over 2 times more likely to die from RCC compared with patients whose specimens exhibited no mononuclear cell infiltration (risk ratio, 2.63; P < .001). After adjusting for the Mayo Clinic SSIGN (stage, size, grade, and necrosis) score, patients with specimens that had mononuclear cell infiltration exhibited a significantly increased likelihood of dying from RCC compared with patients whose specimens had no mononuclear cell infiltration (risk ratio, 1.61; P = .028). CONCLUSIONS. Mononuclear cell infiltration is associated with death from RCC even after multivariate adjustment. Routine documentation of mononuclear cell infiltration is recommended during the pathologic assessment of RCC.
引用
收藏
页码:46 / 53
页数:8
相关论文
共 36 条
[1]   CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2 [J].
Antony, PA ;
Restifo, NP .
JOURNAL OF IMMUNOTHERAPY, 2005, 28 (02) :120-128
[2]   Update on the role of interleukin 2 and other cytokines in the treatment of patients with Stage IV renal carcinoma [J].
Atkins, MB ;
Regan, M ;
McDermott, D .
CLINICAL CANCER RESEARCH, 2004, 10 (18) :6342S-6346S
[3]   Nitric oxide and the immune response [J].
Bogdan, C .
NATURE IMMUNOLOGY, 2001, 2 (10) :907-916
[4]   The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer [J].
Bromwich, EJ ;
McArdle, PA ;
Canna, K ;
McMillan, DC ;
McNicol, AM ;
Brown, M ;
Aitchison, M .
BRITISH JOURNAL OF CANCER, 2003, 89 (10) :1906-1908
[5]   Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects [J].
Burdelya, L ;
Kujawski, M ;
Niu, GL ;
Zhong, B ;
Wang, TH ;
Zhang, SM ;
Kortylewski, A ;
Shain, K ;
Kay, H ;
Djeu, J ;
Dalton, W ;
Pardoll, D ;
Wei, S ;
Yu, H .
JOURNAL OF IMMUNOLOGY, 2005, 174 (07) :3925-3931
[6]   Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma [J].
Cheville, JC ;
Lohse, CM ;
Zincke, H ;
Weaver, AL ;
Blute, ML .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2003, 27 (05) :612-624
[7]  
Childs R, 2001, Curr Opin Urol, V11, P495, DOI 10.1097/00042307-200109000-00008
[8]   Investigating the potential of bevacizumab in other indications: Metastatic renal cell, non-small cell lung, pancreatic and breast cancer [J].
de Gramont, A ;
Van Cutsem, E .
ONCOLOGY, 2005, 69 :46-56
[9]  
Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730
[10]  
Eerola AK, 2000, CLIN CANCER RES, V6, P1875